Paul Song

Company: NKGen Biotech

Job title: Chief Executive Officer & Chairman

Seminars:

Showcasing the Potential of Enhanced NK Cell Therapies for the Treatment of Neurodegenerative Disease: Introducing Troculeucel 12:00 pm

Outlining the mechanism of Troculeucel, a novel cell-based immunotherapy, for treating neurodegeneration Demonstrating early signs of clinical benefit in phase 1, leading to FDA fast track designation for moderate Alzheimer’s Disease and new IND for Parkinson’s Disease Highlighting future directions for Troculeucel in Frototemporal Dementia and post-stroke/TBIRead more

day: Conference Day Two - Track Two